Key points are not available for this paper at this time.
SGLT2i provide a novel therapeutic strategy for chronic cardiorenal syndrome, with their multi-target mechanisms offering new perspectives for combined cardiorenal protection. However, further clinical research is required to optimize treatment protocols and address practical challenges in their application.
Zhu et al. (Mon,) studied this question.